Appendicular Skeletal Muscle Mass Study

NCT ID: NCT04584944

Last Updated: 2020-10-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-01

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is a lot of discussion concerning the normal cut-off points of skeletal mass among different populations worldwide. Genetic and environmental differences most probably lead to different measurements. Defining muscle mass in healthy young adults in Greece will provide information that can be used to determine normal ranges of muscle mass of both sexes and consequently define sarcopenia.

The aim of the study is to define appendicular skeletal muscle mass reference measurements in healthy young adults in Greece. These values can be used to determine sarcopenia cut-offs according to recommendations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction

The reduction of muscle mass in humans is obvious after the age of fifty, with a reduction rate of 3-8% every ten years. The rate of loss accelerates with chronic diseases, sedentary lifestyle, low physical activity, nutritional, environmental and socioeconomic factors .

Sarcopenia has been officially recognized as a disease according to World Health Organization. European Working Group on Sarcopenia in Older People 2 has revised the definition and diagnostic criteria of sarcopenia aiming to encourage more research in the field. In Greece, there are no reference values for muscle strength and muscle mass. Defining these values will permit the investigators to provide a tool that will help to establish country - specific measurements of sarcopenia in Greek population.

Study population-Methods

The study site will be the Outpatient Geriatric Assessment Unit and the Radiology Department of Henry Dunant Hospital Centre, in Athens-Greece.

The study population will be healthy adults that meet the inclusion criteria. The recruitment will be performed using the snowball sampling technique (for instance, through printed material, the marketing department of the hospital, social media, advertising banners, etc.). Stratified random sampling technique will be used to achieve a representative sample size.

Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR-4500 A fan Beam densitometer (Hologic, Inc., Bedford, MA). Hologic Discovery W configured with software version 12.1 (Hologic, Bedford, MA).

Body composition analysis will be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Analysis concerns calculation of body consistency (body fat mass, lean mass water and predicted muscle mass) using Bioelectric Impedance Analysis. Bioelectric Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).

Muscle mass will also be measured by ultrasound -U/S. U/S determines the thickness and transverse incisions of a superficial muscle group. It can measure basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups.

Statistical analysis

It will be performed using the Statistical Package for the Social Sciences -SPSS Version 26.0 (IBM), and R Version 3.6.2.

Descriptive statistics will be presented in percentage proportions, mean values and Standard Deviations (SD) of the variables. In addition, Z-score will be calculated (e.g. Dual-energy X-ray absorptiometry , Bone Mineral density, Dual-energy X-ray absorptiometry % fat, etc.) and T-score ± 2 standard deviations.

Chi-square - χ2 tests or non-parametric tests will be produced to compare qualitative variables. T-test, Analysis of Variance- ANOVA and non-parametric tests will be used in the statistical analysis of quantitative variables within the categories of qualitative variables.

Approval

The protocol has been approved by the Scientific Committee of the Henry Dunant Hospital Centre, in Athens -Greece, and is in accordance with the Code of Ethics of the World Organization for Medical Sciences (CIOMS) as formulated in the Helsinki Declaration on Biological Research.

Informed consent

All participants will be informed in written for the purpose of the research, and the way their personal data are processed (name, address, telephone, e-mail), under the provisions of 2016/679 according to the General Data Protection Regulation (GDPR).

The consent form will describe the legal and transparent way of processing their data, stating the specific purpose for data collection, as well as information about storage of their data. It will also contain a written description of the rights of the participants concerning their data and their ability to revoke consent for the processing of their data. The processing, transfer and storage of data, will also be described, as well as who will have access to their data, and how long the data will be stored for.

Finally, all participants will sign the written informed consent and confidentiality form.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Public Health Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy adult men

Healthy young men, 20- 44 years old

Dual energy X-ray absorptiometry

Intervention Type RADIATION

Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).

Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups.

Healthy adult women

Healthy young women, 20- 44 years old

Dual energy X-ray absorptiometry

Intervention Type RADIATION

Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).

Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dual energy X-ray absorptiometry

Evaluation of the appendicular muscle mass of the limbs will be performed by Dual-Energy X-ray Absorptiometry, using a QDR 4500. Body composition analysis will also be evaluated with TANITA Body Composition Analyzer device,model BC-418MA. Bioelectrical Impedance Analysis measures the body composition using a constant power source (high frequency current 50kHz, 90 μA).

Muscle mass is also going to be measured by using ultrasound -U/S. It measures basic parameters such as muscle volume and spectrum length through the B-Mode imaging with Linear 7-12MHz frequency heads that can reliably determine the thickness and transverse incisions of the superficial muscular Groups.

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bioelectrical Impedance Analysis Ultrasound

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy Greek young adults (20 - 44 years old), with Caucasian characteristics.
2. Able to read and write in Greek language.

Exclusion Criteria

1. Chronic diseases, such as, heart diseases, type II diabetes mellitus and autoimmune diseases.
2. Hyperthyroidism or hypothyroidism (persons with normal thyroid function for six months are included).
3. Malignancies.
4. Seizures of epilepsy, neurodegenerative diseases.
5. Asthma and/or chronic respiratory pulmonary disease-Chronic Obstructive Pulmonary Disease.
6. Metal prefixes.
7. Pacemaker.
8. Systematic medication intake (such as hypolipemic drugs, antihypertensive drugs, antidepressants, glucocorticoids and any other hormonal treatment).
9. Protein formulations and anabolic intake.
10. Hormone intake (testosterone, estrogen, contraceptive, growth hormone, dehydroepiandrosterone.
11. Professional athletes and people with intense physical activity, intensive exercise with weights, long-distance runners (Marathons).
12. Substance use or abuse (cocaine, heroin, amphetamines).
13. Pregnancy.
14. History of hospitalization in Intensive Care Unit
15. History of serious injury
16. Considerable body weight alterations during the previous year (increase or decrease)
17. History of Bariatric surgery
18. Any dietary restriction due to disease (sprue), choice (vegan), or eating disorder (anorexia nervosa).
Minimum Eligible Age

20 Years

Maximum Eligible Age

44 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Henry Dunant Hospital Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anastasia Koutsouri

Role: STUDY_CHAIR

Head of the Outpatient Geriatric Assessment Unit

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Henry Dunant Hospital Center

Athens, , Greece

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Greece

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anastasia Koutsouri

Role: CONTACT

00306944413656

Georgios Soulis

Role: CONTACT

00306947123967

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Anastasia Koutsouri

Role: primary

00306944413656

George Soulis

Role: backup

00306947123967

References

Explore related publications, articles, or registry entries linked to this study.

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jul 1;48(4):601. doi: 10.1093/ageing/afz046. No abstract available.

Reference Type RESULT
PMID: 31081853 (View on PubMed)

Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, Maggi S, Dennison E, Al-Daghri NM, Allepaerts S, Bauer J, Bautmans I, Brandi ML, Bruyere O, Cederholm T, Cerreta F, Cherubini A, Cooper C, Cruz-Jentoft A, McCloskey E, Dawson-Hughes B, Kaufman JM, Laslop A, Petermans J, Reginster JY, Rizzoli R, Robinson S, Rolland Y, Rueda R, Vellas B, Kanis JA. Pitfalls in the measurement of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):269-278. doi: 10.1002/jcsm.12268. Epub 2018 Jan 19.

Reference Type RESULT
PMID: 29349935 (View on PubMed)

Wong AK. A Comparison of Peripheral Imaging Technologies for Bone and Muscle Quantification: a Mixed Methods Clinical Review. Curr Osteoporos Rep. 2016 Dec;14(6):359-373. doi: 10.1007/s11914-016-0334-z.

Reference Type RESULT
PMID: 27796924 (View on PubMed)

Mijnarends DM, Luiking YC, Halfens RJG, Evers SMAA, Lenaerts ELA, Verlaan S, Wallace M, Schols JMGA, Meijers JMM. Muscle, Health and Costs: A Glance at their Relationship. J Nutr Health Aging. 2018;22(7):766-773. doi: 10.1007/s12603-018-1058-9.

Reference Type RESULT
PMID: 30080217 (View on PubMed)

Schaap LA, van Schoor NM, Lips P, Visser M. Associations of Sarcopenia Definitions, and Their Components, With the Incidence of Recurrent Falling and Fractures: The Longitudinal Aging Study Amsterdam. J Gerontol A Biol Sci Med Sci. 2018 Aug 10;73(9):1199-1204. doi: 10.1093/gerona/glx245.

Reference Type RESULT
PMID: 29300839 (View on PubMed)

Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016 Mar;7(1):28-36. doi: 10.1002/jcsm.12048. Epub 2015 Jul 7.

Reference Type RESULT
PMID: 27066316 (View on PubMed)

Chang KV, Hsu TH, Wu WT, Huang KC, Han DS. Association Between Sarcopenia and Cognitive Impairment: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2016 Dec 1;17(12):1164.e7-1164.e15. doi: 10.1016/j.jamda.2016.09.013. Epub 2016 Nov 2.

Reference Type RESULT
PMID: 27816484 (View on PubMed)

Antunes AC, Araujo DA, Verissimo MT, Amaral TF. Sarcopenia and hospitalisation costs in older adults: a cross-sectional study. Nutr Diet. 2017 Feb;74(1):46-50. doi: 10.1111/1747-0080.12287. Epub 2016 Jun 13.

Reference Type RESULT
PMID: 28731551 (View on PubMed)

Beaudart C, Rizzoli R, Bruyere O, Reginster JY, Biver E. Sarcopenia: burden and challenges for public health. Arch Public Health. 2014 Dec 18;72(1):45. doi: 10.1186/2049-3258-72-45. eCollection 2014.

Reference Type RESULT
PMID: 25810912 (View on PubMed)

Lourenco RA, Perez-Zepeda M, Gutierrez-Robledo L, Garcia-Garcia FJ, Rodriguez Manas L. Performance of the European Working Group on Sarcopenia in Older People algorithm in screening older adults for muscle mass assessment. Age Ageing. 2015 Mar;44(2):334-8. doi: 10.1093/ageing/afu192. Epub 2014 Dec 23.

Reference Type RESULT
PMID: 25539836 (View on PubMed)

Panagiotakos DB, Pitsavos C, Stefanadis C. Dietary patterns: a Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. Nutr Metab Cardiovasc Dis. 2006 Dec;16(8):559-68. doi: 10.1016/j.numecd.2005.08.006. Epub 2006 Feb 9.

Reference Type RESULT
PMID: 17126772 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3080234A

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

S-ADHF:Sarcopenia in Patients With ADHF
NCT06298825 NOT_YET_RECRUITING